株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ファーマコゲノミクス技術/テラノスティクス/コンパニオン診断(CDx)市場分析:治療分野別(癌、神経、心血管、免疫疾患)、技術別、およびセグメント予測

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Analysis By Therapeutic Area (Oncology Neurological, Cardiovascular, Immunology Disorders), By Technology, And Segment Forecasts, 2014 - 2025

発行 Grand View Research, Inc. 商品コード 526093
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.53円で換算しております。
Back to Top
ファーマコゲノミクス技術/テラノスティクス/コンパニオン診断(CDx)市場分析:治療分野別(癌、神経、心血管、免疫疾患)、技術別、およびセグメント予測 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Analysis By Therapeutic Area (Oncology Neurological, Cardiovascular, Immunology Disorders), By Technology, And Segment Forecasts, 2014 - 2025
出版日: 2017年06月09日 ページ情報: 英文 150 Pages
概要

当レポートでは、世界のファーマコゲノミクス技術/テラノスティクス/コンパニオン診断(CDx)市場について調査し、市場の概要と治療分野別、技術別、地域別動向、市場に参入する企業の競合動向、プロファイルなどをまとめています。

第1章 調査方法

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • コンパニオン診断:分類
  • 市場セグメンテーション
  • 市場規模と成長見通し
    • 促進因子分析
    • 阻害因子分析
  • 浸透および成長見通しマッピング
  • NGSベースコンパニオン診断の開発
  • コンパニオン診断の償還環境
  • コンパニオン診断の法規制環境
  • コンパニオン診断の法規制問題とリコール
  • SWOT分析
  • 業界分析:ポーターズ

第4章 治療分野別予測および動向分析

  • 動向分析
  • 神経
  • 心血管疾患
  • 免疫疾患
  • その他の疾患

第5章 技術別予測および動向分析

  • 動向分析
  • ポリメラーゼ連鎖反応(PCR)
  • in-situハイブリッド化
  • 免疫組織化学
  • シーケンシング
  • その他の技術

第6章 地域別見通し

  • 市場シェア
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第7章 競合環境

  • 戦略枠組み
  • 市場参入分類
  • 企業プロファイル
目次
Product Code: GVR-1-68038-940-1

The global pharmacogenomics technology (theranostics and companion diagnostics) market is expected to reach USD 18.3 billion by 2025, according to a new report by Grand View Research, Inc. Diagnostics is coming to grips with the wave of pharmacogenomic tests that are followed by new biological therapy introductions. These tests enable cost-effective treatment and also add value to the process of drug-development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to significant source of progress in this market.

In addition, pharmacogenomics testing products aid physicians in individualizing and optimization of patient's therapeutic regimen. Pharmacogenomics and theranostics are paving the way for integrated medicine. Rapid evolution in this group of specialized molecular diagnostic tests are contributing in improvement for assessment of real-time treatment of disease.

However, presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development time lines for gaining the approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy has become a necessary attribute for the success of theranostics.

Further key findings from the report suggest:

Oncology is estimated to account for the largest revenue share owing to the presence of substantial number of products in this segment

Furthermore, precision oncology investigators envision in giving multiple medications, in varied sorts of combinations, in an effort to squelch a tumor rather than just temper its growth

Aforementioned fact is responsible for the estimated revenue share of cancer in pharmacogenomics technology market

Polymerase Chain Reaction (PCR) was the largest revenue grossing segment of the with respect to technology for theranostics

Advantages associated with the use of the PCR technique makes it current workhorse of clinical diagnostics

Moreover, reproducible and precise results produced with the assays without sacrificing the sensitivity are responsible for the estimated share

North American region dominates the market as a consequence of economic incentives for drug developers to pair their products with diagnostics.

Asia Pacific market is projected to showcase fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities

Key players operating include F Hoffman La Roche, Agilent Technologies, Thermo Fisher Scientific Inc., GE Healthcare, Pfizer, Qiagen NV, Leica Biosystems Nussloch GmBH, and Foundation Medicine.

Diagnostic companies are positioning themselves to offer theranostic tools by widening the application of in-vitro diagnostic technologies to include more than just disease detection

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Region Wise Market Calculation
    • 1.1.1 Region Wise Market: Base Estimates
    • 1.1.2 Global Market: CAGR Calculation
  • 1.2 Region based segment share calculation
  • 1.3 Data Analysis
  • 1.4 List of Primary & Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market Variables, Trends& Scope

  • 3.1 Companion Diagnostics: Categorization
    • 3.1.1 Screening and detection
    • 3.1.2 Prognosis
    • 3.1.3 Theranostics
    • 3.1.4 Monitoring
    • 3.1.5 Recurrence
  • 3.2 Market Segmentation & Scope
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Rising adoption of companion diagnostics
      • 3.2.1.2 Accelerating demand for targeted cancer treatment & tailored drugs
      • 3.2.1.2.1 Cancer incidence rate,2016
      • 3.2.1.3 Technological advancements pertaining to sequencing
      • 3.2.1.4 Collaborations between diagnostic and pharma entities
      • 3.2.1.4.1 Business models that benefit CDx developers in early partnering deals
      • 3.2.1.5 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Challenges associated with reimbursement
      • 3.2.2.2 Robustness of the financing environment for diagnostic and research tools companies
      • 3.2.2.3 Laboratory developed tests anticipated to reduce adoption of CDx
  • 3.3 Penetration & Growth Prospect Mapping for Therapeutic Area, 2016
  • 3.4 Development of NGS based Companion Diagnostics
    • 3.4.1 Associated operational challenges
      • 3.4.1.1 Assay turnaround time
      • 3.4.1.2 Sample quantity
      • 3.4.1.3 Unavailability of CROs with CLIA NGS capabilities
    • 3.4.2 Technical and analytical challenges for NGS assays in the clinic
      • 3.4.2.1 Design & QC standardization
      • 3.4.2.2 Post analytical challenges
      • 3.4.2.3 Unavailability of CROs with CLIA NGS capabilities
    • 3.4.3 Strategic challenges for drug and diagnostic developers
  • 3.5 Companion Diagnostics Reimbursement Environment
    • 3.5.1 Issues in technology assessment and payer decision making
    • 3.5.2 Potential risks and benefits of pharmacogenomics from the payer perspective
  • 3.6 Companion Diagnostics Regulatory Environment
    • 3.6.1 Companion diagnostics regulatory environment, U.S.
    • 3.6.2 Companion diagnostics regulatory environment, Europe
    • 3.6.3 Companion diagnostics regulatory environment, Asia Pacific
  • 3.7 Companion Diagnostics Regulatory Issues & Recall
    • 3.7.1 Dako FDA warning letter
    • 3.7.2 HercepTest recall
    • 3.7.3 Cobas KRAS test recall
    • 3.7.4 Cobas BRF V600E test recall
    • 3.7.5 Leica Bond HER2 IHC system
  • 3.8 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) - SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.9 Industry Analysis - Porter's

Chapter 4 Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis

  • 4.1 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market: Therapeutic Area Movement Analysis
  • 4.2 Oncology
    • 4.2.1 Global oncology market, 2014 - 2025 (USD Million)
    • 4.2.2 Lung cancer
      • 4.2.2.1 Global lung cancer market, 2014 - 2025 (USD Million)
    • 4.2.3 Breast cancer
      • 4.2.3.1 Global breast cancer market, 2014 - 2025 (USD Million)
    • 4.2.4 Colorectal cancer
      • 4.2.4.1 Global colorectal cancer market, 2014 - 2025 (USD Million)
    • 4.2.5 Cervical cancer
      • 4.2.5.1 Global cervical cancer market, 2014 - 2025 (USD Million)
    • 4.2.6 Other cancers
      • 4.2.6.1 Global other cancers market, 2014 - 2025 (USD Million)
  • 4.3 Neurology
    • 4.3.1 Global neurology market, 2014 - 2025 (USD Million)
  • 4.4 Cardiovascular Diseases
    • 4.4.1 Global cardiovascular diseases market, 2014 - 2025 (USD Million)
  • 4.5 Immunological Disorders
    • 4.5.1 Global immunological disorders market, 2014 - 2025 (USD Million)
  • 4.6 Other Disorders
    • 4.6.1 Global other disorders market, 2014 - 2025 (USD Million)

Chapter 5 Pharmacogenomics Technology: Technology Estimates & Trend Analysis

  • 5.1 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market: Technology Movement Analysis
  • 5.2 Polymerase Chain Reaction(PCR)
    • 5.2.1 Global polymerase chain reaction market, 2014 - 2025 (USD Million)
  • 5.3 In-situ Hybridization
    • 5.3.1 Global in-situ hybridization market, 2014 - 2025 (USD Million)
  • 5.4 Immunohistochemistry
    • 5.4.1 Global immunohistochemistry market, 2014 - 2025 (USD Million)
  • 5.5 Sequencing
    • 5.5.1 Global sequencing market, 2014 - 2025 (USD Million)
  • 5.6 Other Technologies
    • 5.6.1 Global other technologies market, 2014 - 2025 (USD Million)

Chapter 6 Pharmacogenomics Technology: Regional Estimates & Trend Analysis, by Therapeutic Area & Application

  • 6.1 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market Share by Region, 2016 & 2025
  • 6.2 North America
    • 6.2.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
    • 6.2.2 Market, by technology, 2014 - 2025 (USD Million)
    • 6.2.3 U.S.
      • 6.2.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
      • 6.2.3.2 Market, by technology, 2014 - 2025 (USD Million)
    • 6.2.4 Canada
      • 6.2.4.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
      • 6.2.4.2 Market, by technology 2014 - 2025 (USD Million)
  • 6.3 Europe
    • 6.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
    • 6.3.2 Market, by technology, 2014 - 2025 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
      • 6.3.3.2 Market, by technology, 2014 - 2025 (USD Million)
    • 6.3.4 UK
      • 6.3.4.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
      • 6.3.4.2 Market, by technology, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
    • 6.4.2 Market, by technology, 2014 - 2025 (USD Million)
    • 6.4.3 Japan
      • 6.4.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
      • 6.4.3.2 Market, by technology, 2014 - 2025 (USD Million)
    • 6.4.4 China
      • 6.4.4.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
      • 6.4.4.2 Market, by technology, 2014 - 2025 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
    • 6.5.2 Market, by technology, 2014 - 2025 (USD Million)
    • 6.5.3 Brazil
      • 6.5.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
      • 6.5.3.2 Market, by technology, 2014 - 2025 (USD Million)
  • 6.6 MEA
    • 6.6.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
    • 6.6.2 Market, by technology, 2014 - 2025 (USD Million)
    • 6.6.3 South Africa
      • 6.6.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
      • 6.6.3.2 Market, by technology, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy framework
  • 7.2 Market participation categorization
  • 7.3 Company Profiles
    • 7.3.1 Illumina Inc.
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Financial Performance
      • 7.3.1.3 Product Benchmarking
      • 7.3.1.4 Strategic Initiatives
    • 7.3.2 F Hoffman La Roche
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Financial Performance
      • 7.3.2.3 Product Benchmarking
      • 7.3.2.4 Strategic Initiatives
    • 7.3.3 Qiagen NV
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Financial Performance
      • 7.3.3.3 Product Benchmarking
      • 7.3.3.4 Strategic Initiatives
    • 7.3.4 Myriad Genetics Inc.
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Financial Performance
      • 7.3.4.3 Product Benchmarking
      • 7.3.4.4 Strategic Initiatives
    • 7.3.5 Agilent Technologies
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Financial Performance
      • 7.3.5.3 Product Benchmarking
      • 7.3.5.4 Strategic Initiatives
    • 7.3.6 Foundation Medicine, Inc
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Financial Performance
      • 7.3.6.3 Product Benchmarking
      • 7.3.6.4 Strategic Initiatives
    • 7.3.7 Leica Biosystems Nussloch GmBH
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Financial Performance
      • 7.3.7.3 Product Benchmarking
      • 7.3.7.4 Strategic Initiatives
    • 7.3.8 Merck & Co Inc
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Financial Performance
      • 7.3.8.3 Product Benchmarking
      • 7.3.8.4 Strategic Initiatives
    • 7.3.9 Oxford Cancer Biomarkers Ltd.
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Financial Performance
      • 7.3.9.3 Product Benchmarking
      • 7.3.9.4 Strategic Initiatives
    • 7.3.10 Astra Zeneca
      • 7.3.10.1 Company Overview
      • 7.3.10.2 Financial Performance
      • 7.3.10.3 Product Benchmarking
      • 7.3.10.4 Strategic Initiatives
    • 7.3.11 Thermo Fisher Scientific, Inc.
      • 7.3.11.1 Company Overview
      • 7.3.11.2 Financial Performance
      • 7.3.11.3 Product Benchmarking
      • 7.3.11.4 Strategic Initiatives
    • 7.3.12 Beckman Coulter Inc.
      • 7.3.12.1 Company Overview
      • 7.3.12.2 Financial Performance
      • 7.3.12.3 Product Benchmarking
      • 7.3.12.4 Strategic Initiatives
    • 7.3.13 Abbott Laboratories
      • 7.3.13.1 Company Overview
      • 7.3.13.2 Financial Performance
      • 7.3.13.3 Product Benchmarking
      • 7.3.13.4 Strategic Initiatives
    • 7.3.14 Pfizer
      • 7.3.14.1 Company Overview
      • 7.3.14.2 Financial Performance
      • 7.3.14.3 Product Benchmarking
      • 7.3.14.4 Strategic Initiatives
    • 7.3.15 Focus Diagnostics
      • 7.3.15.1 Company Overview
      • 7.3.15.2 Financial Performance
      • 7.3.15.3 Product Benchmarking
      • 7.3.15.4 Strategic Initiatives
    • 7.3.16 AmeriPath Inc
      • 7.3.16.1 Company Overview
      • 7.3.16.2 Financial Performance
      • 7.3.16.3 Product Benchmarking
      • 7.3.16.4 Strategic Initiatives
    • 7.3.17 Bristol Myers Squibb
      • 7.3.17.1 Company Overview
      • 7.3.17.2 Financial Performance
      • 7.3.17.3 Product Benchmarking
      • 7.3.17.4 Strategic Initiatives
    • 7.3.18 Novartis Ag
      • 7.3.18.1 Company Overview
      • 7.3.18.2 Financial Performance
      • 7.3.18.3 Product Benchmarking
      • 7.3.18.4 Strategic Initiatives

List of Tables

  • TABLE 1 Healthcare expenditure levels, 2015
  • TABLE 2 North America pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 3 North America oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 4 North America pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 5 U.S. pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 6 U.S. oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 7 U.S. pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 8 Canada pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 9 Canada oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 10 Canada pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 11 Europe pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 12 Europe oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 13 Europe pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 14 Germany pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 15 Germany oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 16 Germany pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 17 UK pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 18 UK oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 19 UK pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 20 Asia Pacific pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 21 Asia Pacific oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 22 Asia Pacific pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 23 Japan pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 24 Japan oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 25 Japan pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 26 China pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 27 China oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 28 China pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 29 Latin America pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 30 Latin America oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 31 Latin America pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 32 Brazil pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 33 Brazil oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 34 Brazil pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 35 MEA pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 36 MEA oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 37 MEA pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 38 South Africa pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
  • TABLE 39 South Africa oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 40 South Africa pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Cost per raw megabase (Mb) of DNA sequence (USD)
  • FIG. 12 Cost per genome
  • FIG. 13 Necessary alliances for development of successful companion diagnostics
  • FIG. 14 Expected rise in expenditure for cancer treatment (USD Million)
  • FIG. 15 Market restraint relevance analysis (Current & future impact)
  • FIG. 16 Penetration & growth prospect mapping for therapeutic area, 2016
  • FIG. 17 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 18 Porter's Five Forces Analysis
  • FIG. 19 Companion diagnostics & pharmacogenomics market: Therapeutic area outlook key takeaways
  • FIG. 20 Companion diagnostics & pharmacogenomics market: Application movement analysis
  • FIG. 21 Global oncology market, 2014 - 2025 (USD Million)
  • FIG. 22 Global lung cancer market, 2014 - 2025 (USD Million)
  • FIG. 23 Global breast cancer market, 2014 - 2025 (USD Million)
  • FIG. 24 Global colorectal cancer market, 2014 - 2025 (USD Million)
  • FIG. 25 Global cervical cancer market, 2014 - 2025 (USD Million)
  • FIG. 26 Global other cancers market, 2014 - 2025 (USD Million)
  • FIG. 27 Global neurology market, 2014 - 2025 (USD Million)
  • FIG. 28 Global cardiovascular diseases market, 2014 - 2025 (USD Million)
  • FIG. 29 Global immunological disorders market, 2014 - 2025 (USD Million)
  • FIG. 30 Global other disorders market, 2014 - 2025 (USD Million)
  • FIG. 31 Companion diagnostics & pharmacogenomics market: Technology outlook key takeaways
  • FIG. 32 Global pharmacogenomics technology (theranostics and companion diagnostics) market: Technology movement analysis
  • FIG. 33 Global polymerase chain reaction market, 2014 - 2025 (USD Million)
  • FIG. 34 Global in-situ hybridization market, 2014 - 2025 (USD Million)
  • FIG. 35 Global immunohistochemistry market, 2014 - 2025 (USD Million)
  • FIG. 36 Global sequencing market, 2014 - 2025 (USD Million)
  • FIG. 37 Global other technologies market, 2014 - 2025 (USD Million)
  • FIG. 38 Regional market place: Key takeaway
  • FIG. 39 Companion diagnostics & pharmacogenomics regional outlook, 2016 & 2025
  • FIG. 40 North America pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 41 U.S. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 42 Canada. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 43 Europe pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 44 Germany. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 45 UK. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 46 Asia Pacific pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 47 Japan. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 48 China. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 49 Latin America. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 50 Brazil. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 51 Middle East & Africa. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 52 South Africa pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
  • FIG. 53 Strategy framework
  • FIG. 54 Participant categorization
Back to Top